This federal contract award is for $206,590 for whole exome sequencing (WES), RNA sequencing, and DNA methylation sequencing services provided by Psomagen Inc., a subsidiary of Macrogen, Inc. The contract was awarded by the National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health (NIH), with a period of performance ending on March 4, 2021.
The contract was awarded sole-source to Psomagen Inc. as they were determined to be the only responsible source capable of performing the required services, which involve the use of specialized sequencing kits and platforms to characterize diverse breast cancer samples. Psomagen has extensive experience supporting NIH and other federal agencies through genomics and bioinformatics contracts and grants. While this contract did not have a set-aside, Psomagen is a subsidiary of the larger Macrogen, Inc. organization, which holds multiple large Indefinite Delivery Vehicle (IDV) contracts with agencies like the USDA and NIH to provide comprehensive genomics services across a range of federal research initiatives.